At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 387 enrolled
Drug / intervention
BCX7353drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Study to Evaluate the Long-term Safety of Daily Oral BCX7353 in Subjects With Type I and II Hereditary Angioedema
In Brief
A Phase 3 clinical trial evaluating BCX7353 for Hereditary Angioedema and 2 related conditions. Completed, enrolled 387 participants across 87 sites in 20 countries.
Detailed Summary
This is an open-label study to evaluate the long term safety and effectiveness of oral treatment with BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II Hereditary Angioedema (HAE).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHereditary Angioedema, HAE, Prophylaxis
CountriesAustralia, Austria, Denmark, France, Germany, Hong Kong, Hungary, Israel, Italy, New Zealand, North Macedonia, Poland, Serbia, Slovakia, South Africa, South Korea, Spain, Switzerland, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
Enrollment StartFeb 2018
First PostedMar 2018
Primary CompletionApr 2022
TodayJul 2026
First PostedMar 21, 2018
Enrollment StartFeb 16, 2018
Primary CompletionApr 27, 2022
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 8.3 years ago
Interventions
BCX7353drug
BCX7353 mg oral capsules administered once daily